Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 4, Issue 9, Pages e814
Publisher
Springer Nature
Online
2013-09-26
DOI
10.1038/cddis.2013.312
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers
- (2012) Anurag Singh et al. CELL
- Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1
- (2012) Jie Chen et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Downregulation of alpha-fetoprotein expression by LHX4: a critical role in hepatocarcinogenesis
- (2011) Tzu-Min Hung et al. CARCINOGENESIS
- Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer
- (2011) Noriaki Sunaga et al. INTERNATIONAL JOURNAL OF CANCER
- Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma
- (2011) Masashi Yanae et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations
- (2011) Jeeyun Lee et al. JNCI-Journal of the National Cancer Institute
- Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma-Rationale for Comprehensive Mutation Profiling
- (2011) J. E. Chaft et al. MOLECULAR CANCER THERAPEUTICS
- Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
- (2011) N. Sunaga et al. MOLECULAR CANCER THERAPEUTICS
- Berberine Inhibits Human Hepatoma Cell Invasion without Cytotoxicity in Healthy Hepatocytes
- (2011) Bing Liu et al. PLoS One
- Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation
- (2010) Ke Liang et al. CANCER CELL
- Genetic Screen Identifies Insulin-like Growth Factor Binding Protein 5 as a Modulator of Tamoxifen Resistance in Breast Cancer
- (2010) B. Y. Ahn et al. CANCER RESEARCH
- Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor-Activating Mutations
- (2010) C. Yamamoto et al. CANCER RESEARCH
- KRASmutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach
- (2010) Young-Kwang Yoon et al. MOLECULAR CARCINOGENESIS
- Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells
- (2009) Oras Mistafa et al. BIOCHEMICAL PHARMACOLOGY
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
- (2009) Anurag Singh et al. CANCER CELL
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations
- (2009) In Hae Park et al. INVESTIGATIONAL NEW DRUGS
- Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status
- (2008) Catia Cemeus et al. JOURNAL OF NEURO-ONCOLOGY
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started